Which one of the following would you first need to determine is uniquely expressed in a tumor cell in order to change a “blocking” monoclonal antibody like Herceptin or Cetuximab into a chemotherapeutic “smart bomb” to target just that cell?
A. An overexpressed tumor-specific transcription factor (e.g., c-myc). |
B.
A tumor-specific protein kinase (e.g., BRAFV600E). |
C. A tumor-specific absence of a tumor suppressor like NF1 or p53. |
D.
A tumor-specific G protein (e.g., RasD). |
E. A tumor-specific integral plasma membrane protein. |